Ovulation Inducing Drugs Market Size, Share , Latest Trends, Key Players And Forecast To 2033

The ovulation inducing drugs market size has grown strongly in recent years. It will grow from $4.11 billion in 2023 to $4.42 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to development of clomiphene citrate, introduction of letrozole, regulatory approvals and standardization, emergence of ovulation predictor kits..

The ovulation inducing drugs market size is expected to see strong growth in the next few years. It will grow to $5.7 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to changing lifestyles and delayed childbearing, digital health integration, expanding market reach, rising infertility rates, customized treatment regimens.. Major trends in the forecast period include personalized treatment approaches, advancements in reproductive endocrinology, non-invasive fertility monitoring, rising demand for assisted reproductive technologies, development of novel drug formulations..

Market Overview -
Ovulation-inducing drugs refer to medications that are used to stimulate the ovaries and promote the release of mature eggs (ovulation) in women who are experiencing difficulties with their menstrual cycles or are struggling with infertility. These drugs affect the hormonal balance in the body, specifically targeting the hormones involved in the ovulation process.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13256&type=smp

Rising Prevalence Of Women's Infertility Drives Growth In The Ovulation-Inducing Drug Market
The increasing prevalence of women's infertility is expected to propel the growth of the ovulation-inducing drug market. Women's infertility refers to the biological condition in which a woman cannot conceive a pregnancy or carry it to full term despite engaging in regular, unprotected sexual intercourse for an extended period, typically around a year or more. Ovulation-inducing drugs are used to treat women's infertility to address irregular or absent ovulation issues. These drugs target the hormonal pathways involved in the ovulation process and stimulate the ovaries to release mature eggs. For instance, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2022, there will be 6.1 million women between the ages of 15 and 44 in the US who have trouble becoming pregnant, equivalent to 10% of all women. Furthermore, in June 2022, according to CCRM Management Company LLC, a US medical management company, infertility affects 1 in 4 couples globally on average, rising by 5% to 10% each year. Therefore, the increasing prevalence of women's infertility drives the growth of the ovulation-inducing drug market.

Competitive Landscape -
Major companies operating in the ovulation inducing drugs market report are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Abbvie Inc., Novartis AG, Bayer AG, Sanofi SA, Abbott Laboratories, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceutical Inc., Mylan N.V, Astellas Pharma Inc., Sun Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Dr Reddy's Laboratories Ltd., Intas Pharmaceuticals Limited, Endo International Inc., Ferring Pharmaceuticals Inc., Lupin Limited, LIVZON Pharmaceutical Group Inc., Torrent Pharmaceuticals Ltd., Gedeon Richter plc, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Zydus Pharmaceuticals (USA) Inc., Serum Institute of India Ltd., EMD Serono Inc., Cipla Inc.

Increasing Focus On Drug Developments To Drive The Revenues
Major companies operating in the ovulation-inducing drugs market are developing innovative drugs such as Cetrorelix acetate and getting approval to treat women undergoing controlled ovarian stimulation. Cetrorelix acetate for injection (cetrorelix) is a gonadotropin-releasing hormone (GnRH) antagonist. It prevents premature ovulation in women undergoing in vitro fertilization (IVF). For instance, in August 2022, Akorn Operating Company LLC, a US-based pharmaceutical company, received FDA approval for a generic version of cetrorelix acetate for injection, 0.25 mg (Cetrorelix). This is the initial AP-rated bioequivalent Merck Serono Cetrotide variant that has been authorized. Cetrorelix acetate is a GnRH antagonist that acts by blocking the effects of the gonadotropin-releasing hormone (GnRH). GnRH promotes the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. Moreover, it is used to prevent premature LH surges in women undergoing controlled ovarian stimulation (COS) and to help ensure that all of the eggs have a chance to mature.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/ovulation-inducing-drugs-global-market-report

Key Segments -
The ovulation inducing drugs market covered in this report is segmented -
1) By Drug Class: Hormones, Therapeutics Drugs
2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
3) By End-User: Hospital, Homecare, Specialty Clinics, Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.